Studies How Respiratory Syncytial Virus Affects People of All Ages

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The study looks at people of any age who had a confirmed RSV infection and were treated at a SEHA hospital or healthcare facility between January 2018 and December 2024. It uses their hospital records.

Age

All ages

Sex

All sexes

Disease stage

Confirmed RSV (respiratory syncytial virus) infection

Biomarker or test result

RSV infection confirmed by a laboratory test

Main reasons for not taking part

• Suspected RSV infection that is not confirmed by a laboratory
• Not enough data in the SEHA electronic medical record system

The registry criteria, word for word

What the trial wants to find out

This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:

The group in the trial

• Infants, adults, elderly, and high-risk patients with confirmed RSV infection (2018-2024).

  This retrospective study includes patients of all ages with confirmed Respiratory Syncytial Virus (RSV) infection from January 2018 to December 2024, categorized into four cohorts: (1) Infants and young children, including those with risk factors such as prematurity, low birth weight, and chronic lung or heart disease; (2) Adults aged 18-64 years with or without comorbidities; (3) Elderly adults aged 65 and older, with focus on severe outcomes and mortality; and (4) High-risk individuals across all age groups with underlying conditions such as asthma, COPD, diabetes, immunosuppression, Down syndrome, or cystic fibrosis. No interventions are administered; the study analyzes existing data to assess RSV burden, ICU admissions, long-term health impacts, and associated healthcare costs.